Nurtec (rimegepant) Lactation Clinical Study Published in Breastfeeding Medicine Journal
Biohaven Pharmaceutical Holding Company Ltd. announced that data from a Phase 1, single-center, open-label study evaluating the excretion of a single dose of rimegepant 75 mg in the human milk of healthy lactating women was published in the peer-reviewed journal, Breastfeeding Medicine, the official journal of the Academy of Breastfeeding Medicine.
This study is particularly important as migraine affects more than 30 million women in America and is the most common cause of disability among women of reproductive age (15 – 49 years).1,2 Often for women with migraine, attacks may subside during pregnancy but resume within 4 weeks of childbirth.3 Given a lack of science-based information about migraine medication for nursing mothers, women are often apprehensive about taking their migraine medications while breastfeeding.
The results of the study showed that excretion of rimegepant into human milk is very low and rimegepant was safe and well tolerated by lactating women. It was estimated that on a weight-adjusted basis, a nursing infant would receive <1% of the maternal dose of rimegepant which is much below the commonly cited safety threshold of <10% of the maternal dose. Further, there were no serious adverse events and no participants discontinued the study due to treatment related adverse events.